JP6672140B2 - Ｇｌｐ−１化合物の経口投薬 - Google Patents

Ｇｌｐ−１化合物の経口投薬 Download PDF

Info

Publication number
JP6672140B2
JP6672140B2 JP2016511088A JP2016511088A JP6672140B2 JP 6672140 B2 JP6672140 B2 JP 6672140B2 JP 2016511088 A JP2016511088 A JP 2016511088A JP 2016511088 A JP2016511088 A JP 2016511088A JP 6672140 B2 JP6672140 B2 JP 6672140B2
Authority
JP
Japan
Prior art keywords
peptide
composition
glp
ethoxy
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016511088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519128A5 (OSRAM
JP2016519128A (ja
Inventor
フレミング・セイエル・ニールセン
ペル・サウエルバリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6672140(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2016519128A publication Critical patent/JP2016519128A/ja
Publication of JP2016519128A5 publication Critical patent/JP2016519128A5/ja
Priority to JP2019235054A priority Critical patent/JP7576910B2/ja
Application granted granted Critical
Publication of JP6672140B2 publication Critical patent/JP6672140B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016511088A 2013-05-02 2014-05-02 Ｇｌｐ−１化合物の経口投薬 Active JP6672140B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019235054A JP7576910B2 (ja) 2013-05-02 2019-12-25 Ｇｌｐ－１化合物の経口投薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13166205.8 2013-05-02
EP13166205 2013-05-02
PCT/EP2014/058974 WO2014177683A1 (en) 2013-05-02 2014-05-02 Oral dosing of glp-1 compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019235054A Division JP7576910B2 (ja) 2013-05-02 2019-12-25 Ｇｌｐ－１化合物の経口投薬

Publications (3)

Publication Number Publication Date
JP2016519128A JP2016519128A (ja) 2016-06-30
JP2016519128A5 JP2016519128A5 (OSRAM) 2017-06-15
JP6672140B2 true JP6672140B2 (ja) 2020-03-25

Family

ID=48190381

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016511088A Active JP6672140B2 (ja) 2013-05-02 2014-05-02 Ｇｌｐ−１化合物の経口投薬
JP2019235054A Active JP7576910B2 (ja) 2013-05-02 2019-12-25 Ｇｌｐ－１化合物の経口投薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019235054A Active JP7576910B2 (ja) 2013-05-02 2019-12-25 Ｇｌｐ－１化合物の経口投薬

Country Status (25)

Country Link
US (5) US20160067184A1 (OSRAM)
EP (2) EP3485900A1 (OSRAM)
JP (2) JP6672140B2 (OSRAM)
KR (3) KR20210086717A (OSRAM)
AU (1) AU2014261336B2 (OSRAM)
BR (1) BR112015026325A2 (OSRAM)
CA (1) CA2910903A1 (OSRAM)
CY (1) CY1120730T1 (OSRAM)
DK (1) DK2991671T3 (OSRAM)
ES (1) ES2688462T3 (OSRAM)
HR (1) HRP20181393T1 (OSRAM)
HU (1) HUE040609T2 (OSRAM)
IL (1) IL241813A (OSRAM)
LT (1) LT2991671T (OSRAM)
MX (3) MX369259B (OSRAM)
MY (1) MY172578A (OSRAM)
PL (1) PL2991671T3 (OSRAM)
PT (1) PT2991671T (OSRAM)
RS (1) RS58039B1 (OSRAM)
RU (1) RU2671406C2 (OSRAM)
SA (1) SA515370075B1 (OSRAM)
SI (1) SI2991671T1 (OSRAM)
SM (1) SMT201800492T1 (OSRAM)
WO (1) WO2014177683A1 (OSRAM)
ZA (2) ZA201507096B (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60321B1 (sr) 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
PL2827885T3 (pl) 2012-03-22 2019-01-31 Novo Nordisk A/S Kompozycje peptydów GLP-1 i ich otrzymywanie
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
RS58636B1 (sr) 2012-03-22 2019-05-31 Novo Nordisk As Kompozicije koje sadrže sredstvo za isporuku i njihova priprema
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
KR20210086717A (ko) * 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6910950B2 (ja) 2015-01-12 2021-07-28 エンテリス・バイオファーマ・インコーポレイテッドＥｎｔｅｒｉｓ Ｂｉｏｐｈａｒｍａ，Ｉｎｃ． 固形経口剤形
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US11196462B2 (en) 2016-02-22 2021-12-07 Qualcomm Incorporated Multi-layer beamforming in millimeter-wave multiple-input/multiple-output systems
MX2020001525A (es) * 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
IL322969A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
BR112020008220A2 (pt) * 2017-10-31 2020-10-27 Medimmune Limited distribuição oral de análogos de peptídeo glp-1
CN111683676B (zh) * 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020023388A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Method of using a gip/glp1 co-agonist for diabetes
KR20250044806A (ko) 2018-07-23 2025-04-01 일라이 릴리 앤드 캄파니 요법을 위한 gip/glp1 공효능제 사용 방법
CA3178366A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Gip/glp1 co-agonist compounds
US11471512B2 (en) * 2019-03-01 2022-10-18 Merck Sharp & Dohme Llc Pharmaceutical compositions of a peptide
WO2021089752A1 (en) 2019-11-07 2021-05-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
JP7777085B2 (ja) 2020-04-29 2025-11-27 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
BR112023000229A2 (pt) * 2020-07-22 2023-01-31 Novo Nordisk As Composto, composição farmacêutica, e, peptídeo
US20230272029A1 (en) * 2020-07-22 2023-08-31 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
WO2022268213A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含glp-1化合物的药物组合物
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
CA3223236A1 (en) 2021-07-15 2023-01-19 Thomas Kvistgaard Vilhelmsen Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CA3223247A1 (en) 2021-07-16 2023-01-19 Thomas Kvistgaard Vilhelmsen Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
IL312672A (en) 2021-11-10 2024-07-01 I2O Therapeutics Inc Ionic liquid compositions
WO2023123063A1 (en) * 2021-12-29 2023-07-06 Guangzhou Dazhou Biomedicine Ltd. Oral delivery
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
KR20230132256A (ko) 2022-03-08 2023-09-15 이정열 오징어 조획장치
WO2023191082A1 (ja) 2022-03-31 2023-10-05 株式会社 メドレックス 低溶解性および／または低膜透過性薬物の吸収性が改善された製剤
KR20230147981A (ko) 2022-04-15 2023-10-24 이정열 어류 탈취기
KR20230167546A (ko) 2022-06-02 2023-12-11 이정열 어류 탈취기
WO2023249087A1 (ja) 2022-06-24 2023-12-28 三生医薬株式会社 医薬組成物およびその製造方法
KR20240018118A (ko) 2022-08-02 2024-02-13 이정열 어류 탈취기
CA3265745A1 (en) * 2022-08-25 2024-02-29 The University Of British Columbia Mucoadhesive pharmaceutical form for the unidirectional release of therapeutic peptidic particles
KR20240055265A (ko) 2022-10-20 2024-04-29 이정열 어류 탈취기
WO2024110614A1 (en) * 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1
KR20250141711A (ko) 2022-12-30 2025-09-29 알지파마 에이에스 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법
KR20250072883A (ko) 2023-11-17 2025-05-26 (주)인벤티지랩 세마글루타이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 리포좀, 이를 포함하는 약학적 조성물 및 이의 제조 방법
WO2025105840A1 (ko) * 2023-11-17 2025-05-22 (주)인벤티지랩 세마글루타이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 리포좀, 이를 포함하는 약학적 조성물 및 이의 제조 방법
WO2025169190A2 (en) 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
KR20250122090A (ko) 2024-02-06 2025-08-13 이정열 어류 탈취기
CN120189496A (zh) * 2024-06-03 2025-06-24 深圳奥礼生物科技有限公司 口服的多肽组合物

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219575A (en) 1986-03-12 1990-04-26 Glaxo Group Ltd Phosphate, substituted alkoxy, or amino-carbonyloxy derivatives of milbemycin, and pesticidal compositions
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
JPH08510205A (ja) 1993-03-29 1996-10-29 ユニバーシティ オブ シンシナティ Ｙｙペプチドのアナログとその用途
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5968899A (en) 1994-06-03 1999-10-19 Tsumura & Co. Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
CZ300837B6 (cs) 1996-08-30 2009-08-26 Novo Nordisk A/S Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69732572T2 (de) 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
CA2271788A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
JP2002517483A (ja) 1998-06-08 2002-06-18 シェーリング コーポレイション 神経ペプチドｙ５レセプターアンタゴニスト
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
JP2002523333A (ja) 1998-07-31 2002-07-30 ノボ ノルディスク アクティーゼルスカブ Ｉｉ型糖尿病を予防するためのｇｌｐ−１及び類似体の利用
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
RU2214418C2 (ru) 1998-12-07 2003-10-20 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас Аналоги glp-1
ATE309197T1 (de) 1999-02-05 2005-11-15 Emisphere Tech Inc Verfahren zur herstellung alkylierter salicylamide
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
EP1154761B1 (en) 1999-02-22 2008-02-20 Merrion Research I Limited Solid oral dosage form containing an enhancer
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
NZ514916A (en) 1999-04-30 2004-06-25 Amylin Pharmaceuticals Inc Exendins and exendin agonists linked to polyethylene glycol polymers
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
CN1191273C (zh) 1999-05-17 2005-03-02 康久化学公司 长效促胰岛肽
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
AU2002239384B2 (en) * 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
JP2004515533A (ja) 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝障害を治療するためのペプチドｙｙおよびペプチドｙｙアゴニスト
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
ES2320979T3 (es) 2001-09-24 2009-06-01 Imperial Innovations Limited Pyy-36 para la reduccion o prevencion de la obesidad.
US20040259952A1 (en) 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
PL372394A1 (en) 2002-02-01 2005-07-25 Pfizer Products Inc. Dry granulated formulations of azithromycin
MXPA04008068A (es) 2002-02-20 2004-11-26 Lilly Co Eli Metodo para administrar moleculas de glp-1.
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
EP2277527A3 (en) 2003-01-17 2011-08-31 Ipsen Pharma Peptide YY analogs
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
EA009366B1 (ru) 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
EP1624882A2 (en) 2003-05-14 2006-02-15 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
DE602004023093D1 (de) 2003-07-11 2009-10-22 Novartis Ag N mit einem abgabemittel in mikronisierter form
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
CN1882356B (zh) 2003-11-20 2015-02-25 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
KR20060109940A (ko) 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
KR20060135661A (ko) 2003-12-18 2006-12-29 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 화합물
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
IN2012DN03921A (OSRAM) 2004-02-11 2015-09-04 Amylin Pharmaceuticals Inc
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
MXPA06010345A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
WO2005089789A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
WO2005089790A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
US20090186811A1 (en) 2004-03-17 2009-07-23 Thue Schwartz Y2 Selective Receptor Agonists for Therapeutic Interventions
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
CN102040537A (zh) 2004-05-06 2011-05-04 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
BRPI0510226A (pt) 2004-05-06 2007-10-23 Emisphere Tech Inc composição farmacêutica sólida, forma de dosagem sólida, método para administrar heparina a um animal, método para tratar ou evitar trombose em um animal, método para preparar uma forma de dosagem sólida de heparina umidecida
US8273794B2 (en) 2004-05-14 2012-09-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
EP1765408B1 (en) 2004-07-08 2015-12-09 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
AU2005271878B2 (en) 2004-07-12 2010-02-18 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
US7994119B2 (en) 2004-07-19 2011-08-09 University Of Cincinnati Compounds for control of appetite
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006084164A2 (en) 2005-02-01 2006-08-10 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
JP2008533104A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１受容体の二量体ペプチドアゴニスト
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2006103661A2 (en) 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
WO2006127948A2 (en) 2005-05-26 2006-11-30 Bristol-Myers Squibb Company N-terminally modified glp-1 receptor modulators
US20090054326A1 (en) 2005-07-11 2009-02-26 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
US8975227B2 (en) 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
MX2007016024A (es) 2005-07-18 2008-03-10 Novo Nordisk As Peptidos novedosos para el uso en el tratamiento contra la obesidad.
JP5693817B2 (ja) 2005-08-19 2015-04-01 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 糖尿病の治療法および体重の減少法
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
CN101268099A (zh) 2005-09-21 2008-09-17 7Tm制药联合股份有限公司 用于治疗性干预的y4选择性受体激动剂
CN101268096A (zh) 2005-09-21 2008-09-17 7Tm制药联合股份有限公司 用于治疗性干预的y2选择性受体激动剂
WO2007061434A2 (en) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
JP2009515993A (ja) 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物
ATE549350T1 (de) 2005-12-07 2012-03-15 Hoffmann La Roche Neuropeptid-2-rezeptor-agonisten
EP1959987A2 (en) 2005-12-08 2008-08-27 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
EP1963343A1 (en) 2005-12-14 2008-09-03 Novo Nordisk A/S Polypeptide protracting tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
CA2654566A1 (en) 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2008003050A2 (en) 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
MX2009002121A (es) 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
PE20080840A1 (es) 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
AR062925A1 (es) 2006-09-22 2008-12-17 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
WO2008070547A1 (en) 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
KR20150091536A (ko) 2007-03-02 2015-08-11 노파르티스 아게 칼시토닌의 경구 투여
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
WO2008154619A1 (en) 2007-06-12 2008-12-18 Smithkline Beecham Corporation Methods for detecting protein in plasma
WO2009007714A2 (en) 2007-07-09 2009-01-15 Imperial Innovations Limited Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
CA2697504A1 (en) 2007-08-29 2009-03-12 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
JP2010539058A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのｔｒａｐ−１４
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
PT2203181T (pt) 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
RU2469728C2 (ru) 2007-11-02 2012-12-20 Эмисфире Текнолоджис, Инк. Способ лечения дефицита витамина b12
US20090124639A1 (en) 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP2011520847A (ja) 2008-05-16 2011-07-21 ノボ・ノルデイスク・エー／エス 遅効型ｙ２及び／又はｙ４レセプターアゴニスト
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
SI2386203T1 (sl) 2008-10-15 2014-03-31 Bayer Cropscience Ag Uporaba ditiin tetrakarboksimidov za zatiranje fitopatogenih gljiv
KR20110097807A (ko) 2008-11-05 2011-08-31 에프. 호프만-라 로슈 아게 뉴로펩티드-2-수용체(ｙ-2ｒ) 작용제 및 이의 용도
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
CA2752437C (en) 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
BRPI1008039A2 (pt) 2009-02-20 2016-10-04 Ipsen Pharma Sas composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
CN102573888A (zh) 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
CN102596228A (zh) 2009-10-13 2012-07-18 霍夫曼-拉罗奇有限公司 神经肽-2受体(y-2r)激动剂
WO2011058165A1 (en) 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011080103A1 (en) * 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20110311621A1 (en) 2010-03-16 2011-12-22 Paul Salama Pharmaceutical compositions and methods of delvery
US9040660B2 (en) 2010-04-20 2015-05-26 Novo Nordisk A/S Long-acting gastrin derivatives
JP5827218B2 (ja) * 2010-04-30 2015-12-02 株式会社三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
RS60321B1 (sr) * 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
WO2013009545A1 (en) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
RS58636B1 (sr) 2012-03-22 2019-05-31 Novo Nordisk As Kompozicije koje sadrže sredstvo za isporuku i njihova priprema
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
PL2827885T3 (pl) 2012-03-22 2019-01-31 Novo Nordisk A/S Kompozycje peptydów GLP-1 i ich otrzymywanie
US20150141336A1 (en) 2012-05-29 2015-05-21 Novo Nordisk A/S Pancreatic Peptide Compounds and Use
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
ES3041720T3 (en) 2012-07-01 2025-11-14 Novo Nordisk As Use of long-acting glp-1 peptides
KR20210086717A (ko) * 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
SG11201508469YA (en) 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
SI3068421T1 (sl) 2013-11-15 2019-08-30 Novo Nordisk A/S Selektivne spojine PYY in njihova uporaba
WO2016128974A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents
ES3019234T3 (en) 2015-06-12 2025-05-20 Novo Nordisk As Selective pyy compounds and uses thereof
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
CN111683676B (zh) 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物

Also Published As

Publication number Publication date
CA2910903A1 (en) 2014-11-06
JP7576910B2 (ja) 2024-11-01
US10278923B2 (en) 2019-05-07
EP2991671A1 (en) 2016-03-09
SA515370075B1 (ar) 2017-08-27
US20250213485A1 (en) 2025-07-03
MX369259B (es) 2019-11-04
DK2991671T3 (en) 2018-10-08
BR112015026325A2 (pt) 2017-07-25
KR20210086717A (ko) 2021-07-08
RS58039B1 (sr) 2019-02-28
CY1120730T1 (el) 2019-12-11
HUE040609T2 (hu) 2019-03-28
IL241813A (en) 2017-12-31
PT2991671T (pt) 2018-11-05
ES2688462T3 (es) 2018-11-02
AU2014261336B2 (en) 2019-02-28
KR20160002945A (ko) 2016-01-08
EP2991671B1 (en) 2018-08-15
KR20180115814A (ko) 2018-10-23
SI2991671T1 (sl) 2018-10-30
KR102272671B1 (ko) 2021-07-06
ZA201806791B (en) 2019-06-26
RU2671406C2 (ru) 2018-10-31
HRP20181393T1 (hr) 2018-11-02
JP2020073533A (ja) 2020-05-14
MX2018012166A (es) 2020-09-02
JP2016519128A (ja) 2016-06-30
MY172578A (en) 2019-12-03
US12239739B2 (en) 2025-03-04
US20170312225A1 (en) 2017-11-02
MX2019013123A (es) 2019-12-05
SMT201800492T1 (it) 2018-11-09
AU2014261336A1 (en) 2015-10-08
US20160067184A1 (en) 2016-03-10
PL2991671T3 (pl) 2019-01-31
EP3485900A1 (en) 2019-05-22
WO2014177683A1 (en) 2014-11-06
RU2015147876A (ru) 2017-06-06
US20190216739A1 (en) 2019-07-18
MX2015015009A (es) 2016-03-09
LT2991671T (lt) 2018-09-25
US20250262159A1 (en) 2025-08-21
ZA201507096B (en) 2020-01-29

Similar Documents

Publication Publication Date Title
JP6672140B2 (ja) Ｇｌｐ−１化合物の経口投薬
US11759502B2 (en) Compositions of GLP-1 peptides and preparation thereof
KR102647171B1 (ko) Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
JP7239495B2 (ja) 経口投与用固形組成物
TW202015722A (zh) 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN103260608A (zh) 包含glp-1激动剂和n-(8-(2-羟基苯甲酰)氨基)辛酸盐的固体组合物
US20220280611A1 (en) Solid composition comprising a pyy compound and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
KR102266299B1 (ko) Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20151225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200304

R150 Certificate of patent or registration of utility model

Ref document number: 6672140

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250